Twist Bioscience Co. (NASDAQ:TWST) Shares Bought by Hillsdale Investment Management Inc.

Hillsdale Investment Management Inc. lifted its stake in shares of Twist Bioscience Co. (NASDAQ:TWST) by 0.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 78,000 shares of the company’s stock after purchasing an additional 300 shares during the period. Hillsdale Investment Management Inc. owned approximately 0.13% of Twist Bioscience worth $3,625,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Van ECK Associates Corp raised its holdings in Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after buying an additional 267 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in shares of Twist Bioscience in the third quarter worth approximately $34,000. US Bancorp DE raised its holdings in shares of Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after acquiring an additional 601 shares during the period. Beaird Harris Wealth Management LLC purchased a new stake in shares of Twist Bioscience in the 3rd quarter valued at approximately $95,000. Finally, KBC Group NV boosted its stake in Twist Bioscience by 71.4% in the 4th quarter. KBC Group NV now owns 2,942 shares of the company’s stock worth $137,000 after purchasing an additional 1,226 shares during the period.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. JPMorgan Chase & Co. increased their target price on Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a report on Tuesday, February 4th. Wolfe Research initiated coverage on Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company. TD Cowen reaffirmed a “buy” rating and set a $58.00 target price on shares of Twist Bioscience in a research note on Tuesday, November 26th. Robert W. Baird upped their target price on Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a report on Tuesday, February 4th. Finally, Barclays set a $58.00 price target on shares of Twist Bioscience and gave the stock an “overweight” rating in a report on Monday, February 3rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Twist Bioscience presently has a consensus rating of “Moderate Buy” and a consensus price target of $54.40.

Twist Bioscience Stock Performance

TWST stock opened at $42.89 on Friday. The firm has a 50 day moving average of $45.40 and a two-hundred day moving average of $45.23. Twist Bioscience Co. has a 12 month low of $27.41 and a 12 month high of $60.90. The company has a market capitalization of $2.56 billion, a price-to-earnings ratio of -12.69 and a beta of 2.15. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm had revenue of $88.70 million during the quarter, compared to analysts’ expectations of $86.96 million. During the same period in the prior year, the company posted ($0.75) earnings per share. Twist Bioscience’s revenue for the quarter was up 24.1% on a year-over-year basis. As a group, equities analysts anticipate that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Insider Activity

In other Twist Bioscience news, CEO Emily M. Leproust sold 5,200 shares of the company’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $256,620.00. Following the completion of the sale, the chief executive officer now directly owns 667,318 shares in the company, valued at $32,932,143.30. This represents a 0.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Paula Green sold 918 shares of the firm’s stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $40.91, for a total value of $37,555.38. Following the completion of the sale, the senior vice president now directly owns 130,912 shares in the company, valued at approximately $5,355,609.92. This represents a 0.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 31,552 shares of company stock valued at $1,500,289. Insiders own 3.01% of the company’s stock.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.